MAPK3 and ovarian carcinoma: Moreover, a recent study further disclosed that ERK1/2 inhibitors effectively ameliorate eccDNA-harboring ovarian cancers characterized by constitutive ERK1/2 phosphorylation (Sun et al., 2015).